EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

Graph_RG: Dominating CASP16 's Small Molecule Affinity Prediction Subcategory—A Pose‐Free Framework for Billion‐Scale Virtual Screening

Haiping Zhang

Proteins: Structure, Function, and Bioinformatics · 2026-01 · 94 (1) · 286-294

DOI: 10.1002/prot.70010 ↗
AstrattDettalji biblijografiċi

Astratt

ABSTRACT Protein–ligand interaction prediction is pivotal in early‐stage drug development, enabling large‐scale virtual screening, drug optimization, and reverse target searching. In this work, we present Graph_RG, our top‐performing model in the CASP16 small molecule track's protein–ligand affinity prediction category, achieving a N‐weighted Kendall's Tau of 0.42—significantly outperforming other submissions (second‐best: 0.36). Beyond accuracy, Graph_RG is noncomplex dependent, hence exhibits exceptional computational efficiency, operating > 100 000× faster than conformation‐search dependent prediction methods, thus enabling billion‐ to 10‐billion‐scale screening on standard servers. We further discuss the potential improvements for Graph_RG, including dataset optimization, atomic vector representation enhancements, and model architecture upgrades. We also introduce the potential broader applications in large‐scale drug screening, reverse target identification, and GPCR‐specific drug discovery. We also point out the development of an interactive web platform hosting Graph_RG and its derivative models to enhance accessibility. By integrating community feedback and iterative model refinement, this initiative bridges the gap between AI‐driven predictions and practical drug discovery, fostering advancements in both computational methodologies and biomedical applications.

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →